|
|
Volumn 337, Issue 12, 1997, Pages 851-852
|
|
Pharmacologic advances in the treatment of schizophrenia
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CLOZAPINE;
DOPAMINE 2 RECEPTOR;
HALOPERIDOL;
NEUROLEPTIC AGENT;
OLANZAPINE;
RISPERIDONE;
SERTINDOLE;
ADULT;
AGRANULOCYTOSIS;
CLINICAL TRIAL;
CROSSOVER PROCEDURE;
DOUBLE BLIND PROCEDURE;
DRUG EFFICACY;
DRUG MECHANISM;
DRUG SAFETY;
EDITORIAL;
EXTRAPYRAMIDAL SYMPTOM;
FEMALE;
HUMAN;
MAJOR CLINICAL STUDY;
MALE;
MULTICENTER STUDY;
PRIORITY JOURNAL;
PSYCHOPHARMACOTHERAPY;
PSYCHOSIS;
SCHIZOPHRENIA;
TREATMENT OUTCOME;
AGRANULOCYTOSIS;
ANTIPSYCHOTIC AGENTS;
CLOZAPINE;
HUMANS;
SCHIZOPHRENIA;
|
|
EID: 0030880882
PISSN: 00284793
EISSN: None
Source Type: Journal
DOI: 10.1056/NEJM199709183371211 Document Type: Editorial |
|
Times cited : (10)
|
|
References (6)
|
